Revelstoke Capital Partners (“Revelstoke”), a growth-oriented healthcare-focused private equity firm, announces it has completed a recapitalization of AOM Infusion (“AOM” or the “Company”). AOM, a specialty infusion provider focused on chronic therapy management, is the ninth investment from Revelstoke Capital Partners Fund III. AOM Infusion provides patients with Intravenous Immunoglobulin (“IVIG”), biologics and other therapies, addressing more than 80 different chronic conditions, with long-term treatment administered by skilled infusion nurses. The Company also provides support services, including skilled infusion nursing administration, pharmacy services, referral management, insurance verification and patient education and training.
Read the full article: Revelstoke Capital Partners Makes Significant Investment in AOM Infusion //
Source: https://www.prnewswire.com/news-releases/revelstoke-capital-partners-makes-significant-investment-in-aom-infusion-302427716.html